RG108‐Conjugated Platinum(IV) Prodrugs: Enhanced Efficacy and Reduced Ototoxicity
Chemistry – A European Journal · 27.05.2026 · 32 (20)
DOI: 10.1002/chem.202600019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, online erschienen am 12.03.2026. Verfasst von Jiyong Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, P. R. C…. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Ototoxicity, Organoplatinum Compounds. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Shandong Provincial Natural Science Foundation, Taishan Scholar Youth Expert Program in Shandong Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Platinum‐based chemotherapeutics remain clinically indispensable for treating various malignancies despite causing severe side effects, with ototoxicity being particularly limiting. This study reports the synthesis and evaluation of platinum(IV) prodrugs incorporating the hearing‐protective ligand RG108. Among the synthesized mono‐ and di‐substituted cisplatin and oxaliplatin derivatives, compound 4 exhibited exceptional antitumor activity with an IC 50 value of 0.07 ± 0.08 µM in FaDu cells. Mechanistic investigations revealed that the enhanced anti‐tumor effect was primarily mediated via the EZH2/SLC47A2 regulatory axis. These prodrugs significantly mitigated ototoxicity, preserving cochlear hair cell viability, stabilizing auditory brainstem response thresholds, and maintaining cochlear basement membrane morphology. Our findings establish a framework for designing dual‐functional platinum agents that synergize antitumor efficacy with organoprotective properties, addressing critical hearing loss limitations of conventional platinum chemotherapy while maintaining robust therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, P. R. China.
- Laboratory For Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, Shandong, P. R. China.
- Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, P. R. China.
ORCID-Profile: Yong Wang
Förderung
- Shandong Provincial Natural Science Foundation
- Taishan Scholar Youth Expert Program in Shandong Province
- Fundamental Research Funds for the Central Universities
- Shandong Second Provincial General Hospital Foundation
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wu, J., Nie, J., Wu, H., Wang, D., Li, Y., Liang, M., Qian, H., & Wang, Y. (2026). RG108‐Conjugated Platinum(IV) Prodrugs: Enhanced Efficacy and Reduced Ototoxicity. Chemistry – A European Journal, 32(20). https://doi.org/10.1002/chem.202600019
Vancouver
Wu J, Nie J, Wu H, Wang D, Li Y, Liang M, et al. RG108‐Conjugated Platinum(IV) Prodrugs: Enhanced Efficacy and Reduced Ototoxicity. Chemistry – A European Journal. 2026;32(20). doi:10.1002/chem.202600019
BibTeX
@article{Wu2026,
author = {Wu, Jiyong and Nie, Jing and Wu, Huina and Wang, Dongbo and Li, Yamei and Liang, Minyan and Qian, Huimei and Wang, Yong},
title = {RG108‐Conjugated Platinum(IV) Prodrugs: Enhanced Efficacy and Reduced Ototoxicity},
journal = {Chemistry – A European Journal},
year = {2026},
volume = {32},
number = {20},
doi = {10.1002/chem.202600019}
}
EUVIMED